Correction: FDA Office Of Women’s Health
This article was originally published in The Pink Sheet Daily
Executive Summary
The first major undertaking for new FDA Assistant Commissioner for Science Linda Tollefson under her duties as head of FDA's Office of Women's Health is likely to be responding to the agency's decision on the over-the-counter switch application for Barr's Plan B contraceptive
You may also be interested in...
FDA Appoints Assistant Commissioner For Science Ahead Of Plan B Decision
Former Center for Veterinary Medicine Deputy Director Linda Tollefson will oversee FDA's Offices of Women's Health and Orphan Products Development.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.